Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Leveraging Cell Death Patterns to Predict Metastasis in Prostate Adenocarcinoma and Targeting PTGDS for Tumor Suppression

September 17, 2024

[Scientific Reports] The role of Prostaglandin D2 Synthase in prostate adenocarcinoma was examined through in vitro experiments, single-cell, and Mendelian randomization analysis. Programmed cell death score is elevated in patients with higher Gleason scores, higher T stage, biochemical recurrence, and higher prostate-specific antigen levels.

Human Intermediate Prostate Cancer Stem Cells Contribute to the Initiation and Development of Prostate Adenocarcinoma

September 16, 2024

[Stem Cell Research] Investigators developed a customized medium to culture primary human intermediate prostate cells, which were transplanted into male immunodeficient NCG mice to examine tumorigenicity in vivo.

The Multifaceted Role of the Stroma in the Healthy Prostate and Prostate Cancer

September 10, 2024

[Journal of Translational Medicine] Scientists focus on the characteristics and functions of the prostate associated fibroblasts and of the extracellular matrix in health and cancer.

Associations Between Glucocorticoid Use and Major Adverse Cardiovascular Events in Patients with Prostate Cancer Receiving Antiandrogen: A Retrospective Cohort Study

September 10, 2024

[Prostate Cancer and Prostatic Diseases] Patients with prostate cancer on androgen deprivation therapy and enzalutamide, or abiraterone with 5 mg or 10 mg daily total prednisolone/prednisone were followed up for major adverse cardiovascular events.

Widespread PSA Testing for Prostate Cancer Causes Overdiagnosis in Europe

September 10, 2024

[Tampere University] According to the international study, the widespread use of prostate-specific antigen (PSA) testing has significantly increased the incidence of prostate cancer in Europe. As a result, the disease burden has increased without clear evidence of the benefits of diagnosing the disease.

Integrative Proteogenomic Profiling of High-Risk Prostate Cancer Samples From Chinese Patients Indicates Metabolic Vulnerabilities and Diagnostic Biomarkers

September 6, 2024

[Nature Cancer] Scientists performed a comprehensive proteogenomic characterization of localized high-risk PCa utilizing paired tumors and nearby tissues from 125 Chinese male patients, with the primary objectives of identifying potential biomarkers, unraveling critical oncogenic events and delineating molecular subtypes with poor prognosis.

Major Funding Boost Aims to Advance Research on Bone Metastasis in Breast and Prostate Cancers

September 6, 2024

[News-Medical.net] Breast Cancer Now and Prostate Cancer Research have joined forces to fund up to £600,000 of new research to tackle the spread of both cancers to the bones, known as bone metastasis.

Machine Learning Based Androgen Receptor Regulatory Gene-Related Random Forest Survival Model for Precise Treatment Decision in Prostate Cancer

September 5, 2024

[Heliyon] A consensus androgen receptor regulatory gene-related signature was developed by integrating a total of 101 algorithm combinations of 10 machine learning algorithms. They evaluated the value of AR regulatory gene-related signatur in predicting patient prognosis and the therapeutic effects of the various treatments.

3D Small-Scale Dosimetry and Tumor Control of 225Ac Radiopharmaceuticals for Prostate Cancer

September 5, 2024

[Scientific Reports] Researchers collected digital autoradiographs across whole tissues to generate 3D dose volumes and used them to evaluate the simultaneous tumor control and regional kidney dosimetry of a novel therapeutic radiopharmaceutical for prostate cancer, [225Ac]Ac-Macropa-PEG4-YS5, in mice.

Convergent Alterations in the Tumor Microenvironment of MYC-Driven Human and Murine Prostate Cancer

September 5, 2024

[Nature Communications] Scientists performed extensive single-cell RNA-sequencing and molecular pathology of the comparative biology between human prostate cancer and key stages in the disease evolution of a genetically engineered mouse model of prostate cancer.

Low-Dose Abiraterone plus Olaparib as a Late-Line Treatment for McRpc Patients Without BRCA1/2 Mutations: A Multicenter Retrospective Pilot Study

September 5, 2024

[Scientific Reports] Researchers found that treatment with low-dose abiraterone plus olaparib as a late-line treatment for mCRPC could lead to prostate-specific antigen and symptom progression-free survival in selective cases even without BRCA1/2 mutations.

Intrinsic ADRB2 Inhibition Improves CAR-T Cell Therapy Efficacy against Prostate Cancer

September 5, 2024

[Molecular Therapy] To inhibit ADRB2-mediated inhibitory signaling, we downregulated ADRB2 in CAR-Tcells via RNA interference, assessed different parameters, and compared them with conventional second-generation CAR-T cells.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.